Angiodynamics SEC Filings

AngioDynamics, Inc. filed a Form S-8 to register 4,700,000 shares of common stock for issuance under its 2020 Equity Incentive Plan, as approved by shareholders on November 14, 2023 and November 12, 2024.

The filing also includes a Reoffer Prospectus covering the potential resale, from time to time, of up to 2,529,068 shares by certain employees and officers who acquired awards under the plan. The company will receive no proceeds from sales by the selling stockholders, while bearing registration expenses. AngioDynamics’ common stock trades on Nasdaq as “ANGO,” and the last reported sale price was $11.82 per share on October 20, 2025.

Shares outstanding were 41,076,119 as of September 18, 2025; this is a baseline figure, not the amount being registered or resold.

AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.

Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.

James C. Clemmer, President, CEO and a director of AngioDynamics, Inc. (ANGO), reported an insider purchase of common stock on 10/09/2025. The filing shows a purchase of 10,000 shares at a weighted average price of $11.15, with trade prices in the range $11.10 to $11.17. After the transaction the reporting person beneficially owns 882,529 shares.

The filing is a standard Section 16 Form 4 disclosing a direct purchase by the reporting person. The filer notes the purchase occurred in multiple transactions and offers to provide a breakdown of quantities by price on request. No derivative transactions or dispositions are reported.

AngioDynamics Inc. reported first-quarter fiscal 2026 net sales of $75.7 million, up 12.2% from the prior-year quarter, driven by Med Tech growth of 26.1% (Auryon, NanoKnife, thrombus management) and modest Med Device growth of 2.3%. Gross margin rose 90 basis points to 55.3%. The company recorded a net loss of $10.9 million (loss per share $0.26), an improvement from a $12.8 million loss a year earlier.

The company continues restructuring actions with $2.3 million in charges this quarter and $25.6 million total recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum structure and ongoing minimum annual payments; $2.5 million was paid this quarter and a contingent $3.0 million may be due depending on the Federal Circuit appeal (oral argument set for October 8, 2025). Management maintains a valuation allowance on deferred tax assets and noted continued macroeconomic and supply-chain risks. The company has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025.

AngioDynamics (ANGO) requests shareholder votes at its Annual Meeting on November 10, 2025, including election of two Class I directors, ratification of Deloitte & Touche LLP as auditor and an advisory "Say-on-Pay" vote. Shareholders of record as of September 18, 2025 (41,076,119 shares) may vote in person or virtually at www.virtualshareholdermeeting.com/ANGO2025. The Board describes its enterprise risk oversight process, delegating specific risks to committees and noting the Audit Committee met eight times and includes an audit committee financial expert. CEO compensation was largely performance-based (67% target) and the CEO-to-median employee pay ratio is approximately 44:1. The proxy discloses director retainer and equity grant practices, Compensation Committee use of Meridian for benchmarking, and change-in-control and severance arrangements for executives.

Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.

Divisadero Street Capital and related entities report ownership of material stakes in AngioDynamics common stock. The filing shows Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 3,395,430 shares, representing 8.4% of the class, while Divisadero Street Partners, L.P. and its GP report 3,054,469 shares (approximately 7.5%). The reported positions are held with shared voting and dispositive power only; no reporting person asserts sole voting or sole dispositive power.

The filing states that all reported securities are directly owned by advisory clients of Divisadero Street Capital Management, LP and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. The filing includes a joint filing agreement and a control-person identification exhibit.